Friday, May 8, 2026
← Back to archivePolicy
Policy•Fierce Biotech•May 7, 2026
From drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’
background ▾
- •AstraZeneca's proprietary AI tools (Reinvent, QCS, Development Agent) are delivering measurable efficiency gains—halving molecular discovery timelines and targeting 50% reduction in CMC development time—directly supporting the company's $80B revenue goal by 2030
- •GSK and BMS are explicitly linking AI adoption to R&D productivity and cycle-time reduction (BMS targeting 30% reduction), with GSK leveraging AI for post-acquisition value identification in its M&A strategy
- •Watch for: regulatory implications if AI-driven patient selection (QCS) materially changes trial outcomes in the Datroway phase 3; competitive AI capability gaps among mid-cap and smaller pharmas; and whether announced cycle-time reductions translate to pipeline advancement and approvals within 18-24 months
AstraZenecaGSKBristol Myers SquibbDatroway
→ Read original articlePolicy•Endpoints News•May 7, 2026
Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
background ▾
- •FDA is willing to reconsider a cell therapy that has been rejected twice, indicating potential for regulatory flexibility or new evidence supporting approval
- •The partnership between Atara and Pierre Fabre continues pursuing this asset despite previous setbacks, suggesting confidence in the program's viability
- •Key uncertainty: what specific regulatory modifications or additional data will be required for a successful resubmission attempt
Atara BiotherapeuticsPierre Fabre Pharmaceuticals
→ Read original articlePolicy•Fierce Biotech•May 8, 2026
Chutes & Ladders—Biopharma veteran takes her CEO Cue
background ▾
- •Kyverna Therapeutics hired a chief commercial officer as its mivocabtagene autoleucel (CAR-T) for stiff person syndrome approaches potential approval as the first CAR-T for autoimmune disease following phase 2 success
Cue BiopharmaKyverna TherapeuticsAnavex Life SciencesCUE-401mivocabtagene autoleucel
→ Read original articlePolicy•Fierce Pharma•May 8, 2026
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
background ▾
- •FDA's reconsideration of Ebvallo rejection indicates a potential shift in willingness to accept single-arm trial data for serious/rare disease indications, reversing its initial stance
- •The decision raises hopes for similar reversals of other rejections, including uniQure's gene therapy, potentially signaling broader regulatory recalibration
- •Watch for the FDA's final decision on Ebvallo and whether this signals systematic policy changes in how the agency evaluates single-arm evidence for cell and gene therapies
uniQureEbvallo
→ Read original articlePolicy•STAT News•May 8, 2026
Why we left the FDA: Six former officials share their stories
background ▾
- •Senior FDA leadership including the former CDER director has departed during the Trump administration, suggesting potential organizational instability at a critical drug review center
Market Access
Market Access•Fierce Biotech•May 7, 2026
Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication
background ▾
- •ANG003 addresses a significant unmet need in CF-associated EPI by potentially reducing pill burden from 40 to 3 daily, improving patient adherence and quality of life—a major commercial differentiator versus current PERT standards
- •Blackstone's substantial $250M commitment signals confidence in Anagram's synthetic enzyme platform and reflects growing investor interest in rare CF complications; the funding enables acceleration toward Phase 2 and potential commercialization
- •Watch Phase 2 trial readout comparing ANG003 to Creon on efficacy, safety, and pill burden reduction; regulatory pathway clarity and payer reception will be critical given current treatment burden and global PERT shortages
Blackstone Life SciencesAnagram TherapeuticsAbbVieANG003Creon
→ Read original articleMarket Access•Fierce Biotech•May 7, 2026
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
background ▾
- •Roche's $750M+ acquisition of PathAI represents a major strategic bet on AI-driven digital pathology as a core diagnostic capability, particularly for oncology and metabolic disease precision diagnosis
- •PathAI's recent FDA qualification of its AI tool for NASH clinical trial assessment (AIM-NASH) validates the regulatory pathway for AI diagnostics and de-risks the acquisition value
- •Integration into Roche Diagnostics signals intent to scale PathAI's platform globally and bundle it with Roche's companion diagnostics expertise, creating a formidable AI-enabled oncology diagnostics platform that could reshape precision medicine workflows
RochePathAIAIM-NASH
→ Read original articleMarket Access•Fierce Pharma•May 8, 2026
Pre-launch efforts linked to lasting drug awareness edge: report
background ▾
- •Pre-launch physician awareness creates sustained competitive advantages in oncology, supporting investment in early education campaigns
- •Market timing and awareness-building strategies during development may have outsized commercial returns compared to post-launch promotion
ZoomRx
→ Read original articleMarket Access•Fierce Pharma•May 8, 2026
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
background ▾
- •Angelini's $4.1B acquisition of Catalyst Pharmaceuticals is a major entry strategy into the U.S. rare disease market anchored by Firdapse
- •Firdapse's blockbuster potential and existing regulatory approval in the U.S. provide immediate commercial value versus early-stage pipeline assets
- •Monitor regulatory clearance timelines, integration progress, and Firdapse's commercial performance post-acquisition to assess deal value creation
Angelini PharmaCatalyst PharmaceuticalsFirdapse
→ Read original articleMarket Access•Fierce Pharma•May 8, 2026
The timing is right for psychedelics manufacturer Optimi Health's IPO
background ▾
- •Trump's executive order on psychedelics research creates favorable market conditions for companies like Optimi Health seeking public capital
- •Psychedelics sector momentum is driving IPO activity, though clinical validation and regulatory approval timelines remain unclear
Optimi Health
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•May 7, 2026
Ascendis axes IL-2 program in retreat from oncology expansion
background ▾
- •Ascendis is exiting internal oncology development entirely and returning to rare endocrinology, its core competency area, despite generating positive IL-2 phase 1/2 data
- •The IL-2 asset showed improved OS versus historical controls but failed to justify continued internal investment relative to company strategy
- •The company is exploring partnering or out-licensing TransCon IL-2 β/γ rather than pursuing internal development, suggesting potential value recognition despite deprioritization
Ascendis PharmaEyconisBristol Myers SquibbTransCon IL-2 β/γonvapegleukin alfaTransCon TLR7/8 Agonist
→ Read original articleClinical Trials•Endpoints News•May 7, 2026
Astellas touts data from early test of stem cell-derived eye therapy
background ▾
- •Astellas advances stem cell-derived therapy for age-related eye disease with early positive signals in high-dose patients
- •Limited patient numbers and early-stage data preclude definitive efficacy assessment; Phase 2 readout will be critical for clinical validation
Astellas Pharmastem cell-derived eye therapy (investigational)
→ Read original articleClinical Trials•Fierce Biotech•May 7, 2026
BeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial
background ▾
- •BeOne discontinued its only pan-KRAS inhibitor (BGB-53038) just as the RAS field heats up following Revolution Medicines' phase 3 success and AbbVie's strategic financing of Kestrel Therapeutics
- •Phase 2 RA trial halt for BGB-45035 based on emerging data signals potential safety or efficacy concerns requiring data review before next steps
- •Watch for BeOne's analysis of BGB-45035 rheumatoid arthritis data and whether discontinued targets are genuinely replaced by alternative modalities or represent strategic retreat from these areas
BeOne MedicinesEnsem TherapeuticsCSPC Zhongqi Pharmaceutical TechnologyBG-60366BGB-53038BG-89894
→ Read original articleClinical Trials•Fierce Biotech•May 7, 2026
Antibodies that stop measles from stabbing cells could become new treatments for the surging virus, study suggests
background ▾
- •Four neutralizing antibodies targeting measles hemagglutinin and fusion proteins show promise in preventing viral cell entry and replication in animal models, representing the first serious characterization of protective human antibodies against measles despite 60+ years of vaccine use.
- •No approved antibodies or antivirals currently exist for measles, creating a clear unmet medical need given that immunocompromised individuals and infants cannot safely receive the MMR vaccine and measles continues to resurge globally with >10 million annual cases.
- •Critical next step: Selection of appropriate animal models (non-human primates or ferrets with canine distemper) and advancement to IND-enabling studies; clinical translation timeline and commercial partner identification will be key indicators of development trajectory.
La Jolla Institute for ImmunologyGeorgia State UniversityOhio State UniversityMeasles monoclonal antibodies (four candidates identified, unnamed)
→ Read original articleClinical Trials•Fierce Biotech•May 7, 2026
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
background ▾
- •ENTR-601-44 achieved only 2.36% dystrophin restoration in low-dose cohort, dramatically missing consensus expectations of 10-14% and trailing Avidity's del-zota by a wide margin, representing a potentially fatal setback for Entrada's competitive positioning
- •Entrada identified lower plasma exposure in juvenile DMD patients as the mechanistic cause and cites preclinical evidence suggesting a steep nonlinear dose-response relationship that could enable catch-up at higher doses
- •Q4 higher-dose cohort readout is critical to validating whether Entrada can recover and remain a viable alternative to the Novartis-backed program; failure to demonstrate meaningful improvement would likely end the program
Entrada TherapeuticsAvidity BiosciencesNovartisENTR-601-44delpacibart zotadirsen
→ Read original article